sacituzumab govitecan
gilead sciences
['tropics-02']
#asco2022 rugo tropics-02 phase 3 of sacituzumab vs treatment of physicians choice in hr+ abc. pts had prior endocrine rx and a cdk4/6 inhibitor and 2-4 lines of ct. pfs as primary endpoint.
Professor of Medicine, Stanford University; breast cancer doc